Strides Pharma Science Ltd Upgraded to Hold on Improved Technicals and Valuation

Technical Trend Improvement Spurs Upgrade

The primary catalyst for the rating upgrade is the shift in Strides Pharma’s technical outlook. The technical grade has moved from mildly bearish to mildly bullish, signalling a positive momentum shift in the stock’s price action. Key technical indicators reveal a mixed but improving picture: while the Moving Average Convergence Divergence (MACD) remains mildly bearish on both weekly and monthly charts, the daily moving averages have turned mildly bullish, suggesting short-term upward momentum.

Bollinger Bands show a bullish signal on the monthly timeframe, contrasting with a mildly bearish weekly reading, indicating potential for price expansion. The Dow Theory assessment also reflects this duality, with a mildly bullish monthly trend offsetting a mildly bearish weekly trend. Meanwhile, the On-Balance Volume (OBV) indicator has improved to mildly bullish on the monthly scale, hinting at increasing buying pressure.

Despite some bearish signals from the KST oscillator and weekly MACD, the overall technical environment has improved sufficiently to justify a more positive stance. This technical upgrade aligns with the stock’s recent price performance, which saw a 2.57% gain on the day of the rating change, closing at ₹853.20, up from the previous close of ₹831.80.

Financial Trend: Strong Quarterly Results Bolster Confidence

Strides Pharma’s financial trend has been a significant factor in the upgrade. The company reported a remarkable 133.64% growth in net profit for Q3 FY25-26, with a profit after tax (PAT) of ₹204.91 crores, representing a 128.0% increase quarter-on-quarter. This marks the tenth consecutive quarter of positive results, underscoring consistent operational strength.

Operating profit to interest coverage ratio reached a high of 5.44 times, indicating robust ability to service debt. Return on Capital Employed (ROCE) for the half-year stood at 16.05%, the highest recorded, reflecting efficient capital utilisation. Despite a slight decline in profits over the past year by 8.5%, the company’s operating performance remains resilient, supported by steady revenue growth and margin expansion.

Over the last year, Strides Pharma has delivered a 37.48% return to shareholders, significantly outperforming the Sensex’s 8.53% return in the same period. The stock’s three-year cumulative return of 505.66% dwarfs the Sensex’s 33.79%, highlighting its strong long-term performance despite recent profit pressures.

Valuation: Attractive Metrics Amid Peer Comparison

Valuation metrics also contributed to the upgrade. Strides Pharma’s ROCE of 15.6% and an enterprise value to capital employed ratio of 2.2 indicate a very attractive valuation relative to its historical averages and peer group. The stock currently trades at a discount compared to its peers’ average historical valuations, offering potential upside for value-oriented investors.

However, the company’s market capitalisation grade remains modest at 3, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The current price of ₹853.20 is below the 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹551.00, suggesting a recovery phase in the stock price.

Quality Assessment: Mixed Long-Term Fundamentals

While the short-term financial and technical outlooks have improved, the quality parameters present a more nuanced picture. The company’s long-term fundamental strength is relatively weak, with an average ROCE of 7.27% over the past five years. Net sales have grown at a modest annual rate of 9.32%, and operating profit has increased by 15.52% annually over the same period, indicating moderate growth.

Debt servicing remains a concern, with a high Debt to EBITDA ratio of 6.58 times, signalling elevated leverage and potential risk in adverse market conditions. Additionally, 30.6% of promoter shares are pledged, which could exert downward pressure on the stock price during market downturns, adding a layer of risk for investors.

Stock Performance Relative to Market Benchmarks

Strides Pharma’s stock performance has been impressive over multiple time horizons. While it has slightly underperformed the Sensex in the short term—declining 1.05% over the past week versus Sensex’s 2.71% fall, and down 0.76% over the past month compared to Sensex’s 3.96% drop—the stock’s year-to-date return of -5.45% is marginally better than the Sensex’s -6.11%.

More notably, the stock has delivered exceptional long-term returns, with a 5-year return of 104.58% compared to the Sensex’s 58.74%, and a 10-year return of 71.87%, albeit below the Sensex’s 224.65%. This performance reflects the company’s ability to generate consistent shareholder value despite sectoral and macroeconomic challenges.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Strides Pharma Science Ltd’s rating from Sell to Hold by MarketsMOJO reflects a balanced assessment of the company’s current position. Improved technical indicators and a strong quarterly financial performance have enhanced the stock’s appeal, while valuation metrics remain attractive relative to peers. However, concerns over long-term fundamental strength, debt levels, and promoter share pledging temper enthusiasm.

Investors are advised to monitor the company’s ability to sustain profit growth and manage leverage effectively. The Hold rating suggests cautious optimism, recognising the stock’s recovery potential while acknowledging inherent risks in the pharmaceutical sector’s competitive and regulatory environment.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today